For Healthcare Professionals Outside the US

KISQALI is indicated for the treatment of women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone‑releasing hormone (LHRH) agonist.

HR+/HER2- metastatic breast cancer is a

Now's the moment to decide...
What comes next?

After diagnosis of HR+/HER2– metastatic breast cancer, strength comes first

After diagnosis of HR+/HER2– metastatic breast cancer

strength comes first

KISQALI is the first and only CDK4/6 inhibitor with 3 FIRST-LINE indications backed by evidence from 3 PHASE III TRIALS1-4

Explore the evidence
New
Premenopausal

with an
AI + LHRH agonist

Discover more
New
Postmenopausal

with
FULVESTRANT

Discover more
Postmenopausal

with an
AI

Discover more

AI, aromatase inhibitor; CDK, cyclin-dependent kinase; HER2–, human epidermal growth factor receptor 2–negative; HR+, hormone receptor–positive; LHRH, luteinizing hormone-releasing hormone.

References: 1. KISQALI [Summary of Product Characteristics]. Novartis Pharma AG; 2018. 2. Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA‑7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915. 3. Ibrance [Summary of Product Characteristics]. Pfizer Limited; 2016. 4. Verzenios [Summary of Product Characteristics]. Eli Lilly and Company; 2018.